Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the… byPallavi MadhirajuDecember 11, 2023